Evidence map›Paper›PMID 36171121›Full record

ArticleInternal medicine (Tokyo, Japan)2022

Persistent SARS-CoV-2 Infection in a Patient with Nephrotic Syndrome under Rituximab Therapy: Successful Treatment with a Combination of Remdesivir and Monoclonal Antibodies.

Akihiro Shimizu, Izumi Shirai, Kyohei Ogawa, Akane Miura, Kotaro Haruhara, Kentaro Oshiro, Akihiko Hamaguchi, Shinya Yokote, Masahiro Okabe, Hiroyuki Ueda and 3 more

Open access · diamondAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 1 country.

Akihiro ShimizuDivision of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University Kashiwa Hospital, Japan.
Izumi ShiraiDivision of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University Kashiwa Hospital, Japan.
Kyohei OgawaDivision of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University Kashiwa Hospital, Japan.
Akane MiuraDivision of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University Kashiwa Hospital, Japan.
Kotaro HaruharaDivision of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University Kashiwa Hospital, Japan.
Kentaro OshiroDivision of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University Kashiwa Hospital, Japan.
Akihiko HamaguchiDivision of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University Kashiwa Hospital, Japan.
Shinya YokoteDivision of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University Katsushika Medical Center, Japan.
Masahiro OkabeDivision of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University Daisan Hospital, Japan.
Hiroyuki UedaDivision of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine, Japan.
Nobuo TsuboiDivision of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine, Japan.
Masato IkedaDivision of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University Kashiwa Hospital, Japan.
Takashi YokooDivision of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine, Japan.
Jikei University Kashiwa hospital · JPJikei University School of Medicine · JPKatsushika Medical Center · JPThe Jikei University Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Rituximab is an effective treatment for frequently relapsing/steroid-dependent nephrotic syndrome, but there is concern about infections caused by humoral immunodeficiency. We herein report a case of prolonged (>7 weeks) severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. A 24-year-old man with minimal change disease treated with rituximab developed SARS-CoV-2 infection. The clinical response to remdesivir was soon transiently abolished. Treatment with casirivimab and imdevimab (REGEN-COV) monoclonal antibodies in combination with remdesivir resulted in complete clearance of the infection. The REGEN-COV antibody cocktail may improve the outcome of SARS-CoV-2 infection in patients with humoral immunodeficiency.

Indexed as

COVID-19Nephrotic SyndromeAdenosine MonophosphateAdultAlanineAntibodies, MonoclonalHumansMaleRituximabSARS-CoV-2Young AdultAdenosine MonophosphateAlanineAntibodies, MonoclonalremdesivirRituximabCOVID-19frequently relapsing/steroid-dependent nephrotic syndromeminimal change diseasemonoclonal antibody therapyREGEN-COVrituximab

Identifiers

PMID36171121
PMCPMC9841105
OpenAlexW4297964547

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.